Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
No. of Pages: 123
There are more than 1400 sustained or controlled release drugs approved all over the world. Revenues within the global generics market reached an estimated value
|
15-Jun-2013
|
2500
|
Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma
No. of Pages: 50
India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also
|
03-Jan-2013
|
2500
|
Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma
No. of Pages: 146
The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for
|
04-Jan-2013
|
2500
|
Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars
No. of Pages: 109
Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars,
|
02-Jan-2013
|
2500
|
Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech
No. of Pages: 110
Macro Analysis
• Performance of the Mature Biotech companies recommended by MP Advisors
in 2012 -report card is very impressive and we expect the positive sentiments
to prevail
|
02-Jan-2013
|
2500
|
Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma
No. of Pages: 131
Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care.
|
01-Jan-2013
|
2500
|
Japan Biosimilar- Active Players In Quest of a Specialty & Niche BS space
No. of Pages: 101
Filgrastim BS and Lantus BS Approval- Encouraging uptake and a lesson to fast track JP approval based on Ex-Japan data!
Remicade biosimilar “NK” – A
|
01-Jan-2016
|
4000
|
LARGE CAP PHARMA US & EU OUTLOOK 2016: MAXIMIZING THEIR STRENGTH ON FEWER THERAPY CLASS, PERSONALIZED MEDICINE, NOVEL TARGET AND BIOSIMILARS FOR FUTURE GROWTH
No. of Pages: 97
Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment
|
17-Mar-2016
|
2000
|
India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry
No. of Pages: 35
2016 will be a crucial for drug makers and consumers. During ‘Make-in-India’ week in Mumbai, Govt. highlighted many amendments or introduction of new policies
|
17-Mar-2016
|
1500
|
JP Giants leaning in for becoming a Speciality Global Pharma
No. of Pages: 91
Sakigake designation – A Push from government to “Innovate”!
“Essential drugs” exemption from Z2 rule- Balancing long listed pricing pressure!
Authorized Generics, Biosimilars, and Patent Litigations -
|
10-Mar-2016
|
2500
|
